Table 1.
Select demographics and baseline characteristics from the BEACON and pharmacodynamic studies
| BEACON study a |
Pharmaco-dynamic study (n = 24) | ||
|---|---|---|---|
| placebo (n = 1,097) | bardoxolone methyl (n = 1,088) | ||
| Age, years (mean ± SD) | 68±9 | 69±10 | 66±9 |
| Female, n (%) | 472 (43) | 462 (42) | 13 (54) |
| Race, n (%) | |||
| White | 848 (77) | 846 (78) | 15 (63) |
| Black | 176 (l6) | 185 (17) | 90 (37) |
| Other | 73 (7) | 57 (5) | 0 (0) |
| eGFR, mL/min/1.73 m 2 (mean ± SD) | 22.5±4.6 | 22.4±4.3 | 29.4±6.9 |
| UACR, mg/g (geometric mean) | 221 | 210 | 159 |
| Serum magnesium, mEq/L (mean ± SD) | 1.72±0.23 | 1.71±0.23 | 1.86±0.16 |
a
Partially reproduced from De Zeeuw et al. [17] (copyright © 2013).